



NEW CLINICAL TRIAL OPEN FOR INCLUSION



PROTOCOL TITLE

Lomustine with or without reirradiation for first progression of glioblastoma: a randomized phase III study (LEGATO)

ALIAS

LEGATO

CTO NUMBER

CTO23011EOR

SPONSOR


EORTC

KEY INCLUSION AND EXCLUSION CRITERIA

Inclusion: Patients with first progression or recurrent glioblastoma after first-line treatment having occurred at least 6 months after the end of prior radiotherapy.
 Measurable disease with a maximum tumour diameter of 5 cm
 Stable or decreasing dose of steroids for 7 days prior to enrolment

Exclusion: Any prior anticancer treatment for recurrent glioblastoma (except surgery)

DESIGN



PRINCIPAL INVESTIGATOR

Naam Katrien Erven
Katrien.erven@zas.be

STUDY COORDINATOR(S)

An Van Extergem
An.vanextergem@zas.be

Steven Traets
Steven.traets@zas.be